Achaogen Awarded $2.4 Million Contract Option by NIAID to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Achaogen Awarded $2.4 Million Contract Option by NIAID to Support Development of LpxC Inhibitors for the Treatment of Serious Bacterial Infections

SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that it has been awarded an additional $2.4 million under an existing contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services.

The award will fund the continued research and development of Achaogen’s LpxC inhibitors, which are novel small molecule agents for the potential treatment of bacterial infections, including those resistant to currently available antibiotics. NIAID funding for the LpxC inhibitor research program now totals $4.4 million and, should the remaining contract option be exercised, the total award would reach $5 million.

“This additional support reflects NIAID's ongoing commitment to advance the development of novel drugs to potentially treat multi-drug resistant gram-negative infections,” said Kenneth Hillan, M.B. Ch.B., Achaogen's Chief Executive Officer. “We are excited to continue development of our LpxC inhibitor antibiotic drug candidates with the crucial support of NIAID whose contribution to this effort is helping to advance what may be the first new mechanism against gram-negative infections in over forty years.”

Achaogen is pursuing an advanced series of LpxC inhibitor compounds that are active against Pseudomonas aeruginosa , a common gram-negative pathogen associated with serious illnesses. LpxC is an essential enzyme for the formation of bacterial membranes in gram-negative bacteria that is highly conserved among gram-negative species. The Company has a goal of nominating a clinical candidate from its LpxC inhibitor research program in 2016 and filing an Investigational New Drug (IND) application in 2017.

About the LpxC Inhibitors LpxC inhibitors have the potential to fill an important unmet medical need in the treatment of gram-negative bacterial infections, and additionally have the potential to treat infections caused by biothreat pathogens. LpxC inhibition would represent the first new mode of action in over forty years for the treatment of antibiotic-resistant gram-negative bacterial infections. Achaogen's LpxC inhibitor program is currently in the preclinical stage of development. As the program continues with contract funding from NIAID, the Company will apply the significant knowledge it has gained from research and clinical studies of LpxC inhibitors.

About NIAID and NIH The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research - at the National Institutes of Health (NIH), throughout the United States, and worldwide - to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov .

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov .

About Achaogen Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing LpxC inhibitors for the treatment of serious bacterial infections including MDR gram-negative bacteria. In addition to its work developing plazomicin, Achaogen is researching and developing other treatments for bacterial infections, including LpxC inhibitors. Achaogen's LpxC inhibitor program has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201500009C. LpxC inhibitors are the second class of molecules from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in clinical, and early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com .

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Achaogen’s expectations regarding (i) the use of funds from the funds from Option 1 under the Company’s agreement with NIAID, (ii) whether Achaogen’s may develop the first new mechanism against gram-negative infections in over forty years, (iii) Achaogen’s goal of nominating a clinical candidate from its LpxC inhibitor research program in 2016 and to file an IND application in 2017 and (iv) the potential for LpxC inhibitors to fill an important unmet medical need in the treatment of gram-negative bacterial infections, and to treat infections caused by biothreat pathogens. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; the risks and uncertainties of commercialization and gaining market acceptance; the risk that bacteria may evolve resistance to an LpxC inhibitor; risks and uncertainties as to Achaogen's ability to raise additional capital to support the development of LpxC inhibitors and its other programs; uncertainties regarding the availability of adequate third-party coverage and reimbursement for newly approved products; Achaogen's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; Achaogen's reliance on third-party contract manufacturing organizations to manufacture and supply its product candidates and certain raw materials used in the production thereof; Achaogen's dependence on its President and Chief Executive Officer; risks and uncertainties related to the acceptance of government funding for certain of Achaogen's programs, including the risk that National Institute of Allergy and Infectious Diseases (NIAID) could terminate Achaogen's contract for the funding of the LpxC inhibitor development program; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Achaogen's patents or proprietary rights; and the risk that Achaogen's proprietary rights may be insufficient to protect its technologies and product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Achaogen does not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

AKAO-G

Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 77

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 119

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 172

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
J. Harmon Tests a Smarter Cannabis Accessory Niche

Updated Category News Views 53

Aisle Space Is the Real Prize Most cannabis accessory launches arrive dressed up like a gimmick and disappear before anyone has reordered them. J. Harmon has a more sensible target: give women products that look deliberate, work in everyday routines and do not demand designer-level money. The brand is set to debut at MJBizCon 2026 in Las Vegas, with LUVBUDS handling...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 102

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 9

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 226

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 23

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading

Top 5 Most Recently Viewed Articles

RTX and Cebu Pacific Forge Strategic Engine Maintenance Alliance

Updated Category News Views 201

Strategic Partnership Between RTX and Cebu Pacific In an exciting development for aviation partnerships, Pratt & Whitney, an RTX (NYSE: RTX) business, and Cebu Pacific have entered into a comprehensive long-term agreement aimed at maintaining the efficiency and reliability of Cebu Pacific’s GTF engine fleet. This strategic collaboration underlines the critical role of...

Continue Reading
Hellenic Music Ensemble Embarks on North American Tour

Updated Category News Views 172

The Hellenic Music Ensemble's Exciting North American Tour The Hellenic Music Ensemble is set to take North American audiences on a mesmerizing journey through Greece's rich musical heritage in 2026. Led by the talented Natassa Bofiliou and Giannis Haroulis, alongside special guest star Judy Kuhn, this tour promises to be a landmark event. Celebrating Greek Composers This...

Continue Reading
University of Maryland's Groundbreaking Fundraising Initiative

Updated Category News Views 258

University of Maryland Launches Its Largest Fundraising Campaign The University of Maryland proudly announces its most ambitious fundraising endeavor to date, aimed at elevating education and research. Titled Forward: The University of Maryland Campaign for the Fearless, this initiative seeks to raise an impressive $2.5 billion. With the goal of advancing the university's...

Continue Reading
New Insights on Dowlais Group Plc's Recent Activity

Updated Category News Views 203

Understanding Recent Trading Disclosures by Dowlais Group Plc As the financial landscape continuously evolves, public disclosures play a crucial role in ensuring transparency, trust, and regulatory compliance. Dowlais Group Plc, a notable player in the market, recently had transaction disclosures that are vital for investors and stakeholders alike. The company's exemplary...

Continue Reading
Stock Market Updates: Gains, Losses, and Oil Inventory Trends

Updated Category News Views 142

Recent U.S. Stock Market Movements As the trading day nears its end, U.S. stock indices show promising trends, with the S&P 500 making notable gains recently. This uptrend reflects a resilient market which continues to respond positively amidst economic fluctuations. Key Market Index Performances On Thursday, the Dow Jones Industrial Average climbed by 0.24%, reaching...

Continue Reading